



Immune Cell Activation project



Automated device for
augmented therapy of combined
T Cells and Nanoparticles
against Tumor

Immune Cell Activation partners



M1 MET-PRO of the
ICA project
January 26th 2022

Contacts:

Immune Cell Activation Web site:
nanospace.immunology@gmail.com

M1 DESCRIPTION OF THE WORK PERFORMED and TECHNICAL SHEET



Preparation of Nanoparticles:

- Assembling of theranostic nano-vectors
- Pilot scale production of hybrid nanoparticles:
 - NANOPRECIPITATION
 - PURIFICATION-CONCENTRATION







Item Type	Units
KIC-SL FMs	36
KIC-SL GMs	16
Reslem FMs	20
Sphinx FMs	18
Sphinx GMs	8
EGSE Equipment	1

- Bioreactor refurbishment for Ground test
- Functional test
- Training of the PI and support



- Hardware training and familiarization with mounting and dismounting of scientific models
- Cytotoxic T cells isolation from peripheral blood

ACHIEVED RESULTS



ESTIMATED TIME OF AVAILABILITY OF THE COMMERCIAL APPLICATION OR PRODUCT:

3 years

NEXT STEPS FOR FUTURE COMMERCIALISATION

The steps following the ICA project, which is essential for the future market introduction of nanoparticles suitable for this purpose, will be as follows:

- Execution of in vivo POC, exploiting the ICA results.
- Execution of Toxicity and Safety tests
- Application for authorization for use on humans to EMA
- Execution of Clinical Phase I, II III
- Marketing Authorization (Phase IV) by EMA.

Phases a)-e) will be conducted by Colorobbia over a period of 5 to 10 years depending on the responses of the regulatory agencies.

